Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-26 increased-dose study in autoimmune pulmonary alveolar proteinosis
jRCT2031260516Not yet recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Responder rate based on change in alveolar-arterial oxygen difference. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on jRCT2031260516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260516.